Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Biovica International publ : strengthens management team

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/06/2019 | 02:01am EST

Biovica, active in cancer diagnostics, today announced that Henrik Winther was appointed SVP Business Development and will be part of the management team. He most recently comes from the role of SVP Precision Diagnostics at Immunovia.

"Henrik possesses a rare combination of scientific expertise and commercial experience. With his many years of diagnostics background, he brings with him tremendous insight and an extensive network of contacts. Henrik is an important piece of the puzzle in Biovica's continued market expansion," said Anders Rylander, CEO of Biovica.

Winther has previously worked as Global VP of Business Development at the Danish diagnostics company Dako and later as General Manager of the Companion Diagnostic (CDx) Division at Agilent Technologies based in California. Earlier in his career, Winther headed the R&D diagnostic reagents development at Dako. Prior to that he was associate professor in anatomy, physiology and cell biology at the University of Copenhagen. He will start at Biovica on November 18.

"For a decade, Companion Diagnostics i.e. patient stratification for the right individualized treatment has been the focus of the industry. Now, the next very important topic to secure safe and effective treatments within personalized cancer medicine is the monitoring of patient response to therapy," said Winther.

"Biovica is in a strong position with its DiviTum test which provides a unique tool to oncologists that allows for a fast, robust and reliable assessment of patients' response to a given treatment. DiviTum really has a great potential as it is already CE marked, has interesting applications, support from key opinion leaders globally and several excellent clinical study results. The pieces are in place to take Biovica to the next level," he said.

Audiocast
When:                          6 December 2019 at 10.00 CET
Where:                            https://tv.streamfabriken.com/biovica-international-q2-2019 or
                                     SE: +46850558369 / DK: +4578150107 / UK: +443333009261 / US: +18335268384
Broadcast language:  in English

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.

Biovica - Best Treatment from Day One
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

https://news.cision.com/biovica-international-ab/r/biovica-strengthens-management-team,c2984506

https://mb.cision.com/Main/14910/2984506/1157110.pdf

https://news.cision.com/biovica-international-ab/i/henrik-winther-bw-s,c2725238

(c) 2019 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOVICA INTERNATIONAL AB (
01/16BIOVICA INTERNATIONAL PUBL : Clinical Cancer Research publishes results supporti..
AQ
2019BIOVICA INTERNATIONAL PUBL : strengthens management team
AQ
2019Q2 INTERIM REPORT : Work with the FDA application progressing as planned
PU
2019Q2 INTERIM REPORT :  Work with the FDA application progressing as planned
AQ
2019BIOVICA INTERNATIONAL PUBL : DiviTum validated as a dynamic biomarker in metasta..
PU
2019BIOVICA INTERNATIONAL PUBL : DiviTum - Strong prognostic marker in operable brea..
AQ
2019BIOVICA INTERNATIONAL PUBL : DiviTum validated as a dynamic biomarker in metasta..
AQ
2019BIOVICA INTERNATIONAL PUBL : strengthens with new R&D Director
AQ
2019BIOVICA ISO 13485 : 2016 certificate renewal
AQ
2019BIOVICA INTERNATIONAL PUBL : will present at the Biomarkers & Precision Medicine..
AQ
More news
Financials (SEK)
Sales 2020 4,60 M
EBIT 2020 -29,0 M
Net income 2020 -36,0 M
Finance 2020 26,0 M
Yield 2020 -
P/E ratio 2020 -10,1x
P/E ratio 2021 -70,7x
EV / Sales2020 74,0x
EV / Sales2021 16,5x
Capitalization 367 M
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 23,10  SEK
Last Close Price 15,55  SEK
Spread / Highest target 48,6%
Spread / Average Target 48,6%
Spread / Lowest Target 48,6%
EPS Revisions
Managers
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving Chief Financial Officer
Karin Mattsson Director-Research & Development
Sector and Competitors